Sep. 10 at 8:10 PM
Elevance Health reaffirmed its 2026 adjusted earnings guidance of at least
$27.00 per diluted share in an SEC Regulation FD filing, while also providing an encouraging update on third-quarter performance. At the Wells Fargo Healthcare Conference, the company said Q3 adjusted EPS is tracking above the outlook provided following its second-quarter results, helped in part by favorable medical benefit expense trends.
Elevance also maintained its target for at least
$6 billion in operating cash flow in 2026 and reiterated its goal of achieving at least 12% adjusted EPS growth in 2027 based on 2026 results. The combination of stable earnings guidance, improving third-quarter trends and strong cash-flow expectations gave investors greater confidence in the company's recovery.
The update was particularly significant as health insurers remain under pressure from rising medical costs and uncertainty surrounding Medicaid.
$ELV